-
-
-
-
-
-
-
Lilly (LLY) to Acquire Loxo Oncology (LOXO) in $8 Billion Deal
-
-
-
-
-
-
-
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)
-
-
-
-
-
-
-
Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer
-
-
-
-
-
-
-
Loxo Oncology (LOXO) Announces FDA Breakthrough Therapy Designation to LOXO-292
-
-
-
-
-
-
-
Loxo Oncology Reports Second Quarter 2018 Financial Results
-
-
-
-
-
-
-
Loxo Oncology to Announce First Quarter 2018 Financial Results
-
-
-
-
-
-
-
Loxo Oncology Reports Fourth Quarter and Year-End 2017 Financial Results
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

